The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

Researchers predicted the likelihood of achieving target T-scores in postmenopausal women with osteoporosis who received denosumab therapy for 10 years.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

A new study suggests that only about 1 in 10 common non-surgical and non-invasive treatments for lower back pain are actually ...

HIGH-DOSE vitamin D supplementation significantly reduces disease activity in patients with clinically isolated syndrome (CIS ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

A systematic review in BMJ Evidence-Based Medicine reveals only 10% of treatments for low back pain offer genuine relief.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Only around 1 in 10 common non-surgical and non-invasive treatments for lower back pain is effective, suggests a pooled data ...

Kennedy Jr., the new head of the Department of Health and Human Services, has suggested that vitamin A supplements are just ...